Chen Zhang

Dr. Chen Zhang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
YYYan-Fa Yu
Yan-Fa Yu
CZChen Zhang
Chen Zhang
YHYi-You Huang
Yi-You Huang
SZSirui Zhang
Sirui Zhang
Qian ZhouQian Zhou
Qian Zhou
HLHai-Bin Luo
Hai-Bin Luo

1 September 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
BZBei Zhang
Bei Zhang
YHYue Huang
Yue Huang
SZSi-Rui Zhang
Si-Rui Zhang
MHMeng-Xing Huang
Meng-Xing Huang
CZChen Zhang
Chen Zhang
HLHai-Bin Luo
Hai-Bin Luo

19 May 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Yan ZhouYan Zhou
Yan Zhou
JLJinjian Li
Jinjian Li
HYHan Yuan
Han Yuan
RSRui Su
Rui Su
YHYue Huang
Yue Huang
岭黄岭 黄
岭 黄
Phosphodiesterase 2 (PDE2) has been regarded as a novel target for the treatment of Alzheimer’s disease (AD). In this study, we obtained (R)-LZ77 as a hit compound with moderate PDE2 inhibitory activity (IC50 = 261.3 nM) using a high-throughput virtual screening method based on molecular dynamics. Then, we designed and synthesized 28 dihydropyranopyrazole derivatives as PDE2 inhibitors. Among them, compound (+)-11h was the most potent PDE2 inhibitor, with an IC50 value of 41.5 nM. The molecular docking of PDE2-(+)-11h reveals that the 4-(trifluoromethyl)benzyl)oxyl side chain of the compound enters the H-pocket and forms strong hydrophobic interactions with L770/L809/F862, which improves inhibitory activity. The above results may provide insight for further structural optimization of highly potent PDE2 inhibitors and may lay the foundation for their use in the treatment of AD.

1 July 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PZPei Zhang
Pei Zhang
MJMei-Yan Jiang
Mei-Yan Jiang
MLMei-Ling Le
Mei-Ling Le
BZBei Zhang
Bei Zhang
Qian ZhouQian Zhou
Qian Zhou
HLHai-Bin Luo
Hai-Bin Luo

27 January 2025 in Molecules
Verified
Journal Article
Open access
PDF file
WLWeihao Luo
Weihao Luo
RLRunduo Liu
Runduo Liu
XCXinlin Cai
Xinlin Cai
Qian ZhouQian Zhou
Qian Zhou
CZChen Zhang
Chen Zhang
Phosphodiesterase-5 (PDE5) is a potent therapeutic target for the treatment of male erectile dysfunction and pulmonary arterial hypertension with several drugs available on the market. However, most of the reported PDE5 inhibitors lack specificity over PDE6, a holoenzyme in eleven PDE families, which may cause various adverse effects. Targeting a unique allosteric pocket has proved to be an effective approach to designing selective PDE5 inhibitors. In the present study, an integrated virtual screening procedure consisting of pharmacophore modeling screening, molecular docking, molecular dynamics simulations, and binding free energy calculations was applied to the discovery of novel PDE5 inhibitors targeting the allosteric pocket. Seven out of thirty-three molecules purchased from the SPECS database (a hitting accuracy of 21%) with novel scaffolds were PDE5 inhibitors with enzymatic inhibition ratios of more than 50% at a concentration of 10 μM. Predicted binding patterns indicate these hits fit well in the allosteric pocket in PDE5. In particular, compound AI-898/12177002 (IC50 = 1.6 μM) demonstrates over 10-fold selectivity towards PDE6, providing a novel scaffold for the optimization of potent and selective PDE5 inhibitors with less adverse effects.

21 January 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
Qian ZhouQian Zhou
Qian Zhou
XWXu-Nian Wu
Xu-Nian Wu
WLWei-Hao Luo
Wei-Hao Luo
QHQing-Hua Huang
Qing-Hua Huang
LFLing-Ling Feng
Ling-Ling Feng
CZChen Zhang
Chen Zhang
Alzheimer’s disease (AD) is a widely recognized type of dementia that leads to progressive cognitive decline and memory loss, affecting a significant number of people and their families worldwide. Given the multifactorial nature of AD, multitarget-directed ligands (MTDLs) hold promise in developing effective drugs for AD. Phosphodiesterase-9 (PDE9) is emerging as a promising target for AD therapy. In this study, by combining a PDE9 inhibitor C33 with the antioxidant melatonin, we designed and discovered a series of pyrazolopyrimidinone derivatives that simultaneously inhibit PDE9 and possess antioxidant activities. Molecular docking, together with dynamics simulations, were applied to accelerate compound design and reduce synthetic work. Four out of the 14 compounds were validated as effective PDE9 inhibitors with comparable antioxidant activity. Notably, compounds 17b and 17d demonstrated IC50 values of 91 and 89 nM against PDE9, respectively, with good antioxidant activities (ORAC (Trolox) of 2.00 and 2.60). This work provides a new approach for designing MTDLs for the treatment of AD and offers insights for further structural modifications of PDE9 inhibitors with antioxidant capacities.